Physician profile
Benjamin Whigham
NPI 1396183240
$1,817.77
in general payments reported to CMS, 2019-2025
15 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.77 · 2020: $61.28 · 2022: $102 · 2023: $399 · 2024: $707 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $302.46 | 2024-2025 | Xdemvy |
| Abbvie INC. | $289.65 | 2022-2025 | Durysta |
| Oyster Point Pharma, INC. | $247.13 | 2023-2025 | Tyrvaya |
| Glaukos Corporation | $221.21 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Sun Pharmaceutical Industries INC. | $198.97 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $153.82 | 2022-2023 | |
| Amgen INC. | $81.73 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $78.52 | 2024-2025 | Rocklatan, Tryptyr |
| Astellas Pharma US INC | $78.20 | 2024-2025 | Izervay |
| Thea Pharma INC. | $41.77 | 2024-2025 | Iyuzeh |
| Harrow Eye, LLC | $37.54 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $25.49 | 2022 | |
| Aerie Pharmaceuticals, INC. | $23.50 | 2020 | |
| Allergan, INC. | $19.20 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Whigham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.